Can 16 ng/mL Whole-Blood THC Accompany Hallucination-Like Symptoms? A Controlled Cannabis Case

Short answer: Yes—in a tightly supervised laboratory cannabis study, one medically screened 30-year-old man reported striking auditory and visual distortions, dissociation, and loss of perceived control after vaporizing plant material containing a nominal 25 mg of THC. His directly assayed whole-blood THC concentration was 16 ng/mL approximately ten minutes after administration ended. The same man’s nominally 25-mg smoked-cannabis session yielded 1 ng/mL whole-blood THC at the corresponding collection point without reported hallucinations. This unusual, documented response establishes that such experiences can occur, not that 16 ng/mL is a hallucination threshold, a psychiatric diagnosis, a driver-impairment cutoff, or proof of causation in another person.

These observations come from Barrett, Schlienz, Lembeck, Waqas, and Vandrey’s 2018 original case report and cross-study comparison, “Hallucinations” Following Acute Cannabis Dosing: A Case Report and Comparison to Other Hallucinogenic Drugs. The distinctive scientific issue is the conjunction of measured whole-blood cannabinoids, administration route, observed inability to function, and unusually intense self-described perceptual phenomena in a single participant. The investigators did not establish a population incidence of hallucinations or a quantitative blood THC–effect curve.

What exactly happened in the controlled experiment?

The person identified as H.C. was an enrolled volunteer in a double-blind, placebo-controlled study of smoked and vaporized cannabis. His acute reaction occurred during one of several scheduled sessions, not during an uncontrolled roadside stop. Researchers used cannabis supplied through the National Institute on Drug Abuse program. The plant material was certified to contain 13.4% THC and 0.03% cannabidiol (CBD), with about 186.6 mg of dried cannabis weighed to provide material containing a nominal 25 mg of THC. That number describes THC contained in the prepared plant, not a directly verified mass delivered to blood or brain.

After a low-fat breakfast, H.C. inhaled vaporized cannabis during a protocol window of approximately ten minutes. He initially developed intense drug effects, then became markedly sedated and had difficulty answering research staff, lifting his head, maintaining steady gait, and completing performance assessments. Researchers later documented his descriptions of auditory sensitivity, distortions of spatial surroundings, tingling, fear, and an out-of-body or dissociative experience. Direct study observations and subsequent self-reports are complementary but different classes of evidence.

Who was studied, and what does the sample size mean?

The unusual event is one individual’s case (n = 1). His parent smoked/vaporized study enrolled 14 healthy adults, including him; a separate oral-cannabis study enrolled 17, yielding 31 participants across the two cannabis projects. Comparison material also came from psilocybin sessions involving 18 adults, dextromethorphan (DXM) sessions involving 12, and salvinorin A sessions involving eight. Those groups do not convert this case report into a prospective incidence or diagnostic-accuracy study of hallucinations. The paper does not establish whether individuals across all archival studies were unique to each dataset, so simply totaling every comparison number as a single independent sample is inappropriate.

H.C. was described as medically and psychiatrically healthy at screening, without a reported personal or family history of psychosis. He had not used cannabis for approximately six years by self-report, although he had historical exposure. His account of a prior dissociative experience with ketamine before surgery is relevant as an observation, but it is not a test of genetic or clinical susceptibility. A negative baseline urine drug screen and breath alcohol result supported the session’s controlled conditions without providing a universal exclusion of every potential influence.

Was THC actually measured in blood, rather than inferred from the dose?

Yes. The study reported quantitative liquid chromatography–tandem mass spectrometry (LC–MS/MS) of whole blood approximately ten minutes after completion of the vaporized dose. In the case participant, the measured concentrations were parent THC 16 ng/mL, active metabolite 11-hydroxy-THC 3 ng/mL, and THC-COOH 17 ng/mL. For other participants at that study time and dose, the reported averages were 14, 2, and 7 ng/mL, respectively. Those are distinct chemical targets measured in the same matrix; THC-COOH is not an interchangeable estimate of psychoactive parent THC.

For this man’s session involving smoking material containing the same nominal 25 mg THC, corresponding whole-blood results were THC 1 ng/mL, 11-hydroxy-THC 1 ng/mL, and THC-COOH 4 ng/mL. The paper says that these measurements were consistent with other participants’ route-specific values. Critically, two concentrations at a selected sampling time do not define absorbed dose, complete concentration–time exposure, or individual brain effect. Whole blood must not be confused with separated serum or plasma or with urine cannabinoid screening. For a basic distinction among testing materials, see the already published guide to biological matrices in forensic toxicology.

Evidence table 1: dose, whole-blood measurements, and observed outcomes

What did observers see versus what did the participant report?

Staff noted functional difficulty during the first approximately 90 minutes: intermittent failure to respond, somnolence, inability to maintain a stable gait, and inability to complete some cognitive assessments. That observation is stronger than an uncorroborated claim that absolutely nothing behavioral occurred. Conversely, the study did not administer a validated driving examination, conduct a psychiatric diagnostic interview during the peak, or establish that all experiences were objective hallucinations rather than intensely altered perception with sedation or dissociation. Each conclusion should remain at its proper level.

The later narrative described voices seeming exaggerated yet difficult to understand, patterns apparently moving across the floor and furnishings, the environment seeming to sink, and an out-of-body experience. He also reported fear, dizziness, nausea, paresthesias, and a sense of paralysis. His own retrospective description is informative about subjective experience, not direct instrumentation of auditory or visual sensory processing. The paper’s quotation marks around “Hallucinations” appropriately signal that the experience is being characterized carefully.

How long did the reported episode last?

The acute reaction developed rapidly after vaporization. The participant’s staff-observed functional difficulties were most prominent during roughly the first 90 minutes, while he later reported that symptoms began waning around three hours. By roughly four hours, the authors said nausea, faintness, dissociation, and sensory alterations had nearly resolved; by five hours he could again complete the laboratory tasks. The investigators reported return of measured cognitive performance, subjective ratings, and vital signs to baseline within about eight hours. This is an observed case timeline, not a generalizable estimate that all cannabis-related hallucinations last eight hours or resolve without intervention.

His vital signs and behavior did not prompt medical intervention under direct research supervision, although being medically monitored is itself a contextual distinction from an unobserved occurrence in the community. One individual’s recovery cannot rule out more serious responses elsewhere. Likewise, the timing of a single blood draw cannot determine what concentration corresponded to every stage of the symptoms or prove that the measured value caused each complaint.

What was the Hallucinogen Rating Scale, and why does it matter?

The investigators used the 59-item Hallucinogen Rating Scale (HRS), whose items cover six dimensions: Intensity, Somaesthesia, Affect, Perception, Cognition, and Volition. Responses use a 0-to-4 ordinal item scale, and subscales average their relevant items. The instrument quantifies reported phenomenology. It does not directly quantify blood THC, prove a psychotic disorder, measure a driver’s lane position, or establish that an allegation in litigation is accurate.

The research team compared the single case’s ratings with means from studies involving smoked, vaporized, or oral cannabis and the classic or atypical hallucinogens psilocybin, DXM, and salvinorin A. The analytic method was a one-sample t-test comparing archival group distributions with the one case’s score. This is an exploratory comparison of subjective dimensions across protocols, not a randomized head-to-head trial in which one subject received all drugs under identical conditions. Between-study differences in dose, participants, session design, and expectations remain material.

Evidence table 2: strong contrasts and informative null findings

Did a high whole-blood THC number explain the abnormal experience?

Not by itself. The observed 16 ng/mL whole-blood THC value was close to the reported 14 ng/mL mean at the same vaporized dose and time point, despite H.C.’s unusually severe subjective reaction. The study therefore illustrates a basic toxicological distinction: the measured concentration describes one chemical state, whereas a particular individual’s response depends on additional unmeasured factors. A study average is not a predictive clinical interval, a case-specific variance estimate, or a tolerance correction. No concentration-specific hallucination risk curve, likelihood ratio, cutoff sensitivity, or individual effect threshold was calculated.

The contrast with 1 ng/mL after a nominally equal smoked dose is also not a controlled vaporizer-versus-pipe causal estimate. Different device delivery efficiencies, inhalation behaviors, thermal losses, and timing can alter exposure. Those factors are plausible considerations, not experimentally isolated explanations for this participant. The HRS Intensity rating after smoking the nominal 25-mg dose was reportedly comparable to that after the adverse vaporized dose even though hallucination-like effects were not reported in the smoking session. This is another warning against equating one global subjective scale with the precise character of an episode.

Can the finding be called cannabis-induced psychosis?

The paper describes an acute adverse event with hallucination-like and dissociative features, not a demonstrated sustained psychotic disorder. It does not document a lasting psychotic syndrome or provide a differential-diagnostic workup capable of excluding every alternative. The participant’s lack of known family history of psychosis was based on screening information, and a single episode cannot establish his underlying susceptibility. A clinician diagnosing a later patient would need contemporaneous examination, symptom duration, substance history, medication and co-exposure information, and the relevant diagnostic criteria, not a one-to-one analogy with this case.

Researchers considered whether CB1-receptor agonism, individual sensitivity, or interactions involving other neuronal systems could contribute. Their hypotheses about genetic variants or serotonin/glutamatergic interactions were not tested in the participant. The plant had little CBD; that alone does not show that CBD would have prevented his reaction. Mechanistic speculation must remain separate from observed whole-blood analytes, observed sedation, and the man’s self-reported perceptual alterations.

Can the Hallucinogen Rating Scale comparisons prove the event was like psilocybin or ketamine?

No. On some HRS dimensions the case rated above comparator group means, but Affect and Cognition scores were materially lower than high-dose psilocybin or DXM comparisons. The pattern therefore did not match every dimension of typical classic-hallucinogen effects. His history of a ketamine-related out-of-body sensation offers a descriptive parallel, not an administered-ketamine comparison in this experiment. DXM, psilocybin, and salvinorin A operate through pharmacologic pathways that cannot be declared identical from one set of ratings.

The authors’ cross-study comparisons were hypothesis-generating. They used different participants, exposure regimens, and study histories; the primary case had no matched within-person DXM or psilocybin condition. Multiple reported comparisons also create interpretive caution, particularly where p values are close to 0.05 and formal multiplicity procedures are not established. Forensic evaluation should resist selecting only the largest between-study differences while ignoring the documented null comparisons.

What does this tell a forensic toxicologist reviewing a driver’s blood sample?

The narrow legitimate point is that strong behavioral and perceptual effects are possible during an observed cannabis exposure, and a particular whole-blood THC value by itself is not a sufficient description of those effects. Nothing in this single-case article validates a 16 ng/mL impairment cutoff or implies that someone with 1 ng/mL is unimpaired. Blood specimen identity, time from collection to analysis, chain of custody, identification criteria, and validated analytical uncertainty matter first. These principles are discussed in the existing confirmatory drug testing guide.

Next, evaluate independent functional evidence. Did an examiner observe unsteady gait, attentional lapses, confusion, abnormal perception, or inability to follow instructions? Were these documented contemporaneously and assessed against competing explanations? In the Barrett case, trained staff directly observed dramatic difficulty, but no legal driving task, collision, standardized field sobriety test, or road-safety endpoint was measured. A forensic opinion cannot transport the participant’s unusual subjective response to a different individual simply because their concentrations resemble his.

Can blood THC reconstruct the inhaled dose or exact time of use?

Not from this case alone. The nominal prepared dose refers to THC content in the plant material, not total THC systemically absorbed. The 16 ng/mL finding was one time-specific whole-blood sample following a known laboratory event. It cannot validate an algorithm that takes an unknown person’s isolated roadside concentration and calculates precisely how much they inhaled, what route they used, when they smoked, or what symptoms they felt. Smoking and vaporization in the same participant gave substantially different concentration measurements following nominally equal plant THC, emphasizing the importance of route and individual circumstances.

Pharmacokinetic interpretation asks about absorption, distribution, metabolism, sampling time, and measurement uncertainty. It is distinct from direct HRS scores and behavioral observations. The already published pharmacokinetics guide provides background for why concentration-time models require assumptions and do not determine a person’s mental state.

What are the most important scientific limitations?

This was an unusually informative single-case report nested within controlled studies, not a representative cohort designed to estimate hallucination prevalence. There was no replicated severe episode in this subject and no population model relating dose or whole-blood THC to perceptual events. The comparison HRS studies were archival and heterogeneous; the t-tests compare one unusual score with group observations. The participant’s perception, fear, and dissociation were reported retrospectively after the most severe period, when he could not complete all laboratory instruments. Staff observed sedation and dysfunction but could not directly verify every reported visual or auditory phenomenon.

Even apparently precise p values in group comparisons address differences among scale ratings under those study conditions, not universal diagnostic rules. No per-person confidence interval for a hallucination risk threshold was reported; assigning one would invent an analysis. The study also lacked a genotype assay, THC brain concentration, repeated peak blood samples mapped to each symptom, and adequate data to rank all explanations for the adverse response. The fair conclusion is a documented possibility with major transfer limits, neither a dismissal of the event nor an unjustified population claim.

How should this original paper be cited and used?

Barrett FS, Schlienz NJ, Lembeck N, Waqas M, and Vandrey R. “Hallucinations” Following Acute Cannabis Dosing: A Case Report and Comparison to Other Hallucinogenic Drugs. Cannabis and Cannabinoid Research. 2018;3(1):85–93. doi:10.1089/can.2017.0052. It supports a specific observed adverse response following a controlled, nominal 25-mg THC vaporized plant dose, with contemporaneous whole-blood analysis and HRS comparisons. It does not demonstrate a universal hallmark symptom, a safe exposure level, a legal impairment rule, or a mechanism proved in the participant.

Forensic reports and clinical summaries should preserve the exact matrix and timing, keep an individual’s description separate from staff-observed behavior, accurately identify the exploratory comparison sample sizes, include the null contrasts, and make clear where the evidence ends. That approach gives the research its evidentiary value without turning one exceptional human experience into an unsupported assertion about a different person’s intoxication or mental state.

Frequently asked questions

Can 16 ng/mL of whole-blood THC cause hallucinations?

In the reported controlled session, a participant with 16 ng/mL whole-blood THC shortly after vaporized cannabis described hallucination-like symptoms and displayed pronounced sedation. The observation does not establish that this concentration reliably causes such symptoms in other individuals or that a specific numeric threshold exists.

Was THC measured in whole blood or in serum?

The case report specifically describes quantitative LC–MS/MS of whole blood. It reported 16 ng/mL parent THC, 3 ng/mL 11-OH-THC, and 17 ng/mL THC-COOH approximately ten minutes after vaporization. Those values should not be relabeled as plasma or serum concentrations.

Did the participant hallucinate after smoking the same nominal THC dose?

No comparable hallucination-like experience was reported for his 25-mg nominal smoked-cannabis session. Its corresponding whole-blood THC was 1 ng/mL, although similar nominal THC content does not prove the same delivered systemic exposure.

Does this case establish cannabis-induced psychosis?

No. It describes acute self-reported sensory distortions and dissociation with directly observed functional difficulty, without documenting a sustained psychotic disorder or proving a complete clinical differential diagnosis.

Were the HRS findings significant for every comparator drug?

No. For example, case Intensity versus maximum DXM was p = 0.13, Perception versus maximum DXM was p = 0.051, and Somaesthesia versus maximum psilocybin was p = 0.23. Other contrasts were significant; the paper reports a mixed multidimensional pattern.

Does the case provide a driving-impairment cutoff or a blood-to-hallucination formula?

No. It includes no on-road driving, legal impaired-driving classification, prospective predictive model, or validated single-person cutoff. An isolated blood result must be interpreted alongside analytical and contemporaneous functional evidence.

Did the effects resolve and is that guaranteed for other patients?

In this subject the investigators reported substantial improvement by about four to five hours and return to baseline on measured outcomes within eight hours. One monitored recovery cannot predict another person’s course or exclude more serious outcomes.